Related Experiment Video

Updated: Oct 11, 2025

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.6K

Cardiac resynchronization therapy in patients with congenital heart disease and systemic right ventricle

Etienne Jacquemart1, Nicolas Combes2, Guillaume Duthoit3

  • 1Université de Paris, PARCC, INSERM, Paris, France.

Heart Rhythm
|December 5, 2021
PubMed

Insights

Cardiac resynchronization therapy (CRT) is effective in patients with congenital heart disease (CHD) and a systemic right ventricle (SRV). Outcomes in SRV patients were comparable to those with a systemic left ventricle, showing high CRT response rates.

Area of Science:

  • Cardiology
  • Congenital Heart Disease
  • Electrophysiology

Background:

  • Systemic right ventricle (SRV) patients form a significant subgroup of congenital heart disease (CHD) patients receiving cardiac resynchronization therapy (CRT).
  • Existing data on CRT outcomes in SRV patients are limited and often conflicting.

Purpose of the Study:

  • To analyze the outcomes of cardiac resynchronization therapy (CRT) in patients with a systemic right ventricle (SRV).
  • To compare CRT response rates in SRV patients versus those with a systemic left ventricle.

Main Methods:

  • Retrospective, multicenter cohort study (2004-2020) involving 85 patients with CHD who received CRT.
  • Defined CRT response as ≥10% increase in systemic ventricular ejection fraction and/or ≥1 grade improvement in NYHA functional class.
  • Included 31 patients with SRV and compared their outcomes to patients with a systemic left ventricle.

Main Results:

  • A total of 85 CHD patients were included, with 31 (36.5%) having SRV.
  • CRT response rates at 6, 12, and 24 months were high in SRV patients (82.6%, 80.0%, 77.8%) and comparable to systemic left ventricle patients (66.7%, 64.3%, 69.6%).
  • Late complications were infrequent, including lead dysfunction, CRT-related infections, and inappropriate ICD shocks.

Conclusions:

  • Approximately one-third of CHD patients receiving CRT in this cohort had an SRV.
  • Cardiac resynchronization therapy (CRT) demonstrates a high response rate in patients with systemic right ventricle (SRV), similar to those with a systemic left ventricle.
  • CRT is a viable and effective treatment option for selected CHD patients with SRV.
Abstract

Keywords:
Cardiac resynchronization therapyCongenital heart diseaseHeart failureSystemic right ventricleTransposition of the great arteries

More Related Videos

Implantation of Total Artificial Heart in Congenital Heart Disease07:27

Implantation of Total Artificial Heart in Congenital Heart Disease

Published on: July 18, 2014

24.8K
Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System10:17

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System

Published on: April 11, 2025

1.0K

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
61
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
63
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
87
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
98
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
52
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
816